Cardiol Therapeutics (TSE:CRDL) Releases Earnings Results

Cardiol Therapeutics (TSE:CRDL) posted its quarterly earnings results on Thursday. The company reported C($0.11) earnings per share (EPS) for the quarter, FiscalAI reports.

Cardiol Therapeutics Stock Down 2.0%

Shares of CRDL traded down C$0.03 during mid-day trading on Friday, hitting C$1.44. 26,778 shares of the company’s stock were exchanged, compared to its average volume of 139,720. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 5.55. The company has a market cap of C$174.98 million, a price-to-earnings ratio of -4.24 and a beta of 0.14. The stock’s 50-day moving average is C$2.04 and its 200-day moving average is C$1.81. Cardiol Therapeutics has a fifty-two week low of C$1.23 and a fifty-two week high of C$3.23.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.